Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.54 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.54 |
| ▸ | DRD4 | P21917 | 6/20 | 0.51 |
| ▸ | DRD2 | P14416 | 5/20 | 0.49 |
| ▸ | HTR7 | P34969 | 2/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9118791 | 0.80 | DRD2 (0.56) | HTR1AADRA1AADRA1BDRD4DRD2 | |
| SCHEMBL3088832 | 0.79 | DRD4 (0.54) | HTR1AADRA1AADRA1BDRD4DRD2 | |
| SCHEMBL7968237 | 0.78 | CYP2D6 (0.58) | HTR1AADRA1AADRA1BDRD4DRD2 | |
| SCHEMBL6958871 | 0.77 | DRD2 (0.50) | HTR1AADRA1AADRA1BDRD4DRD2 | |
| SCHEMBL3196223 | 0.77 | HTR1A (0.57) | HTR1AADRA1AADRA1BDRD4DRD2 | |
| SCHEMBL5356203 | 0.76 | DRD4 (0.55) | HTR1AADRA1AADRA1BDRD4DRD2 | |
| SCHEMBL9006349 | 0.74 | KCNH2 (0.62) | HTR1ADRD4DRD2HTR7DRD3 | |
| SCHEMBL2802108 | 0.74 | CYP1A2 (0.48) | HTR1AADRA1AADRA1BDRD4DRD2 | |
| SCHEMBL2077260 | 0.74 | GRM5 (0.51) | HTR1AADRA1AADRA1BDRD4DRD2 | |
| SCHEMBL2077261 | 0.74 | ADRA2C (0.56) | HTR1AADRA1AADRA1BDRD4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018089433-A1 | PHENYL mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |